Digestive system cancers, including hepatocellular carcinoma, colorectal and gastric tumors, are characterized by high rates of incidence and mortality. Digestive cancers are difficult to diagnose during the early stages, and the side effects of chemotherapy are often severe and may outweigh the therapeutic benefits. Chimeric antibody chimeric antigen receptor T cell (CAR-T) therapy, a novel immunotherapy, has achieved excellent results for the treatment of hematological tumors. However, CAR-T treatment of solid tumors has struggled due to a lack of target specificity, a difficult tumor microenvironment, and T cell homing. Despite the challenges, CAR-T treatment of digestive cancers is progressing. Combining CAR-T with other targets and/or modifying the CAR may represent the most promising approaches for future treatment of digestive cancers.

中文翻译：

---

临床前嵌合抗体嵌合抗原受体 T 细胞在消化系统癌症中的进展

消化系统癌症，包括肝细胞癌、结肠直肠癌和胃肿瘤，具有高发病率和高死亡率的特点。消化系统癌症在早期难以诊断，化疗的副作用通常很严重，可能超过治疗效果。嵌合抗体嵌合抗原受体T细胞（CAR-T）疗法作为一种新型免疫疗法，在治疗血液肿瘤方面取得了优异的效果。然而，由于缺乏靶点特异性、困难的肿瘤微环境和 T 细胞归巢，CAR-T 治疗实体瘤一直在努力。尽管面临挑战，消化系统癌症的 CAR-T 治疗仍在取得进展。将 CAR-T 与其他靶点结合和/或修改 CAR 可能代表未来治疗消化系统癌症的最有希望的方法。